Stivarga (regorafenib) is a small molecule pharmaceutical. Regorafenib was first approved as Stivarga on 2012-09-27. It is used to treat colorectal neoplasms, gastrointestinal stromal tumors, and hepatocellular carcinoma in the USA. It has been approved in Europe to treat colorectal neoplasms. The pharmaceutical is active against serine/threonine-protein kinase B-raf. In addition, it is known to target vascular endothelial growth factor receptor 2. Stivarga's patents are valid until 2032-07-09 (FDA).
|Indication||colorectal neoplasms, gastrointestinal stromal tumors, hepatocellular carcinoma|
|Drug Class||Raf kinase inhibitors|